Table 5.
Summary of Indigenous population enrolment in general population chronic disease randomized controlled trials.
| Location and total study enrolment | Population identity and enrolment | Chronic condition studied in the trial | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | CVD | Dental | Diabetes | HTN | Kidney | Mental illness | Respiratory | ||
| Australia (n = 49,692) | Indigenous, Aboriginal, and Torres Strait Islander (n = 7032, 14.2%) |
– | 14% | – | – | – | 0.002% | 0.1% | – |
| General population (n = 42,660, 85.8%) |
1.5% | 65.9% | 8.0% | 0.2% | 0.4% | 9.6% | 0.3% | ||
| Canada (n = 804) |
First Nations, Inuit and Métis (n = 0, 0%) |
– | – | – | – | – | – | – | – |
| General population (n = 804, 100%) |
7.5% | 34.5% | 23.9% | 18.4% | 2.0% | 9.7% | 4.0% | ||
| New Zealand (n = 654) | Maori and Pacific Islander (n = 96, 14.7%) |
0.8% | 1.7% | – | – | – | – | – | 12.2% |
| General population (n = 558, 85.3%) |
15% | 16.8% | 33.3% | 6.1% | 14.1% | ||||
| US (n = 187,391) | American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander (n = 4180, 2.2%) |
0.1% | 1.4% | 0.1% | 0.4% | 0.01% | 0.01% | 0.1% | 0.2 |
| General population (n = 183,211, 97.8%) |
4.3% | 29.3% | 2.6% | 25.0% | 6.8% | 1.9% | 13.4% | 14.6% | |
| Multiple countries (n = 120,385) | Indigenous (n = 406, 0.3%) |
0.1% | 0.02% | – | 0.1% | – | 0.01% | 0.02% | 0.1% |
| General population (n = 119,979, 99.7%) |
6.6% | 40.3% | 0.04% | 32.6% | 1.0% | 2.0% | 4.3% | 12.8% | |
CVD: cardiovascular disease; HTN: hypertension.
Proportions rounded to 1 decimal place unless <0.05%.